Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Stephanie Balcaitis"'
Autor:
Shannon A Kreuser, Harrison Chinn, Kole R DeGolier, Lisa R Matsumoto, Richard G Ellenbogen, Courtney A Crane, Jennifer L Gardell, Brooke Prieskorn, Stephanie Balcaitis, Amira Davis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Targeted and effective treatment options are needed for solid tumors, including glioblastoma (GBM), where survival rates with standard treatments are typically less than 2 years from diagnosis. Solid tumors pose many barriers to immunother
Externí odkaz:
https://doaj.org/article/15a229533bb54825bf8fdfc63c7e52fa
Autor:
Shannon A Kreuser, Venu G. Pillarisetty, Robert H. Pierce, Nicole A P Lieberman, Courtney A. Crane, Michael C. Jensen, Stephanie Balcaitis, Kimberly S. Smythe, Lisa R Matsumoto, Kole DeGolier, Virginia Hoglund, Katherine J. Brempelis, Chibawanye I. Ene, Amira Davis, Kevin P. Labadie, Harrison Chinn, Richard G. Ellenbogen, Eric C. Holland, Jason K. Yokoyama, Brooke M Prieskorn, Kara White Moyes, Sara K. Daniel, Courtney M Cowan, Jean S. Campbell
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundThough currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors remain resistant t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::042c3f5bc17eab81a652d44c9968c65f
http://europepmc.org/articles/PMC7594542
http://europepmc.org/articles/PMC7594542
Autor:
Stephanie Balcaitis, Lisa R Matsumoto, Amira Davis, Brooke M Prieskorn, Kole R DeGolier, Shannon A Kreuser, Courtney A. Crane, Jennifer L Gardell, Harrison Chinn, Richard G. Ellenbogen
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundTargeted and effective treatment options are needed for solid tumors, including glioblastoma (GBM), where survival rates with standard treatments are typically less than 2 years from diagnosis. Solid tumors pose many barriers to immunothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de15254bd5a5bc76e29bcbb960938428
https://pubmed.ncbi.nlm.nih.gov/33122397
https://pubmed.ncbi.nlm.nih.gov/33122397
Autor:
Courtney A. Crane, Kathryn Brennan, Kristen Haberthur, Sarah Leary, Gail H. Deutsch, Amira Davis, Shannon A Kreuser, Stephanie Balcaitis, Harrison Chinn, Richard G. Ellenbogen, Conrad Winter, Virginia Hoglund
Publikováno v:
Cancer Biology & Therapy. 17:1253-1265
Adult brain tumors establish an immunosuppressive tumor microenvironment as a modality of immune escape, with several immunotherapies designed to overcome this barrier. However, the relationship between tumor cells and immune cells in pediatric brain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01c04308467bdc29ac585ee6fbef700b
https://doi.org/10.1080/15384047.2016.1250047
https://doi.org/10.1080/15384047.2016.1250047
Autor:
Kent J. Weinhold, Joseph P. Balint-Junior, Elizabeth Gabitzsch, Brigitte Sanders-Beer, Stephanie Balcaitis, Julie A. Karl, Younong Xu, Frank R. Jones, Slobodan Paessler
Publikováno v:
Vaccine. 30:7265-7270
Anti-vector immunity mitigates immune responses induced by recombinant adenovirus vector vaccines, limiting their prime-boost capabilities. We have developed a novel gene delivery and expression platform (Ad5 [E1-, E2b-]) that induces immune response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21565972258ce3339f0ab4146682afbf
https://doi.org/10.1016/j.vaccine.2012.09.058
https://doi.org/10.1016/j.vaccine.2012.09.058
Autor:
John H. Lee, Frank R. Jones, Paola D. Vermeer, Stephanie Balcaitis, Bryant G. Wieking, Daniel W. Vermeer, William C. Spanos, Elizabeth Gabitzsch, Younong Xu, Walter T. Lee, Joseph P. Balint, Kimberly M. Lee
Publikováno v:
Cancer gene therapy
Human papillomaviruses (HPVs) are the causative factor for greater than 90% of cervical cancers and 25% of head and neck cancers. The incidence of HPV positive (+) head and neck squamous cell carcinomas (HNSCCs) has greatly increased in the last 30 y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b069ba6cac69d98c99218d1ed75f6ca6
https://doi.org/10.1038/cgt.2012.55
https://doi.org/10.1038/cgt.2012.55
Publikováno v:
Cancer gene therapy
Immunotherapy is a promising approach for the treatment of cancers. Modified adenovirus 5 (Ad5) vectors have been used as a platform to deliver genes encoding tumor associated antigens (TAA). A major obstacle to Ad5 vector immunotherapy has been the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbc9b217e05d321bcf5545f79a3fb8ba
http://europepmc.org/articles/PMC3079015
http://europepmc.org/articles/PMC3079015
Publikováno v:
Glia. 50:48-55
Microglial cells are the resident immune cells of the central nervous system. Their function resembles that of tissue macrophages and, as such, they share many properties with both peripheral macrophages and monocytes. One striking similarity is the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80409dca22d72dfd4100c315a44c1737
https://doi.org/10.1002/glia.20146
https://doi.org/10.1002/glia.20146
Autor:
Yiheng Xie, Stephanie Balcaitis, Henrik Andersen, Bruce R. Ransom, Jonathan R. Weinstein, Thomas Möller, Uwe Karsten Hanisch
Publikováno v:
NeuroReport. 14:2373-2377
Microglia are the resident immune cells of the CNS: they are activated rapidly by CNS damage and perform the function of tissue macrophages. The first steps during microglial activation are currently under intense study, and it is widely believed tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3c4721f5440d4f9bde7cc1d0766b315
https://doi.org/10.1097/00001756-200312190-00017
https://doi.org/10.1097/00001756-200312190-00017
Autor:
Takuya Osada, David S. Hsu, Younong Xu, Andrea Amalfitano, Joseph P. Balint, Arvind Chaudhry, Bruce K. Burnett, Michael A. Morse, Rajesh Dua, Timothy M. Clay, Amy Hobeika, Susan Nguyen, Elizabeth Gabitzsch, Stephanie Balcaitis, Frank R. Jones, Gayathri R. Devi, H. Kim Lyerly
Publikováno v:
Cancer immunology, immunotherapy : CII. 62(8)
First-generation, E1-deleted adenovirus subtype 5 (Ad5)-based vectors, although promising platforms for use as cancer vaccines, are impeded in activity by naturally occurring or induced Ad-specific neutralizing antibodies. Ad5-based vectors with dele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4ca1cd7d045b8c8ca7eb7c1cdeed02
https://pubmed.ncbi.nlm.nih.gov/23624851
https://pubmed.ncbi.nlm.nih.gov/23624851